International Ophthalmology

, Volume 30, Issue 3, pp 267–270

Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

  • Benjamin J. Ernst
  • Andrew J. Barkmeier
  • Levent Akduman
Original Paper

Abstract

To evaluate optical coherence tomography (OCT)-based intravitreal ranibizumab treatment for neovascular age-related macular degeneration (AMD), the charts of consecutive patients who received intravitreal ranibizumab for subfoveal choroidal neovascularization due to AMD were retrospectively reviewed. Patients with less than 6 months follow-up were excluded. OCT was performed at baseline and at monthly intervals for induction therapy. Injections were given monthly until no improvement was observed between successive OCTs. In the maintenance period, reinjections were performed for any recurrence of macular fluid on OCT. Main outcome measures were visual acuity and number of injections given. Twenty-five eyes of 22 patients with mean follow-up of 16 months [standard deviation (SD) = 3.7 months] had mean improvement of 1.6 lines of Snellen visual acuity (SD 2.9, 95% confidence interval 0.48–2.9, P = 0.008). Visual acuity was stable (≤3 lines of visual acuity lost) in 22 eyes (88%). Nine eyes (36%) gained ≥3 lines. Three eyes (12%) lost ≥3 lines. A mean of 6.0 (SD 2.7) injections were given over a follow-up period ranging from 8 to 21 months. We conclude that OCT-based intravitreal ranibizumab treatment for neovascular AMD offered excellent visual acuity results and reduced the number of injections compared with monthly dosing.

Keywords

Age-related macular degeneration Ranibizumab Choroidal neovascularization Optical coherence tomography 

References

  1. 1.
    Rosenfeld PJ, Brown DM, Heier JS et al (2006) MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMedGoogle Scholar
  2. 2.
    Brown DM, Kaiser PK, Michels M et al (2006) ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMedGoogle Scholar
  3. 3.
    Chen Y, Wiesmann C, Fuh G et al (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293:865–881CrossRefPubMedGoogle Scholar
  4. 4.
    Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248CrossRefPubMedGoogle Scholar
  5. 5.
    Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583CrossRefPubMedGoogle Scholar
  6. 6.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) MARINA study group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868–1875CrossRefPubMedGoogle Scholar
  7. 7.
    Falkenstein IA, Cochran DE, Azen SP et al (2008) Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 115:319–323CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Benjamin J. Ernst
    • 1
  • Andrew J. Barkmeier
    • 2
  • Levent Akduman
    • 1
  1. 1.Saint Louis University Eye InstituteSt. LouisUSA
  2. 2.Cullen Eye Institute, Baylor College of MedicineHoustonUSA

Personalised recommendations